Eikon receives FDA clearance to begin EIK1006 prostate cancer trial

Eikon Therapeutics received U.S. FDA clearance for the IND covering EIK1006, its candidate for advanced metastatic prostate cancer. The company plans to launch the Phase 1/2 ARGATE-001 study in patients whose disease has progressed despite established anti-hormonal therapy. Eikon expects dosing to begin in 2027 and preliminary safety and efficacy results in the second half of 2027.

The clearance allows Eikon to move EIK1006 into human testing, creating a clinical development milestone for the company. The timing of trial initiation and preliminary data gives investors the next disclosed milestones for assessing the candidate.

  • 1The U.S. Food and Drug Administration cleared Eikon’s Investigational New Drug application for EIK1006.
  • 2Eikon plans to evaluate EIK1006 in the Phase 1/2 ARGATE-001 study.
  • 3Participant dosing is expected to start in 2027, with preliminary safety and efficacy data expected in the second half of 2027.
  • 4The trial will enroll patients with metastatic androgen-pathway-modulation-resistant prostate cancer whose disease progressed on established anti-hormonal therapy.

Sources